Evidence map›Paper›PMID 26424865›Full record

Trial reportEuropean heart journal2015

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

Emily C O'Brien, DaJuanicia N Simon, Laine E Thomas, Elaine M Hylek, Bernard J Gersh, Jack E Ansell, Peter R Kowey, Kenneth W Mahaffey, Paul Chang, Gregg C Fonarow and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05975320 ("ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.), which is not on this map. Cited by 191 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 5 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05975320 unknown statusnot on this mapstarted 2023, after this paper: background citation

"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.

TypeobservationalSponsorSohag UniversityRan2023 to 2024Enrolled100ConditionsPatients With Atrial Fibrillation Receiving Oral AnticoagulantsArmsWarfarin
3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 5 syntheses or guidelines pooled it, 436 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. VARC-HBR criteria validation in TAVI patients on oral anticoagulation.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Managing bleeds on anticoagulant therapy: a practical guide for clinicians.European heart journal. Acute cardiovascular care · 2026
    Review
  18. Review
  19. Add-on antiplatelet therapy in anticoagulated patients with atrial fibrillation.International journal of cardiology. Heart & vasculature · 2026
    Article
  20. Article

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Emily C O'BrienDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA emily.obrien@duke.edu.
DaJuanicia N SimonDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Laine E ThomasDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Elaine M HylekBoston University School of Medicine, Boston, MA, USA.
Bernard J GershMayo Clinic, Rochester, MN, USA.
Jack E AnsellHofstra North Shore/LIJ School of Medicine, Hempstead, NY, USA.
Peter R KoweyJefferson Medical College, Philadelphia, PA, USA.
Kenneth W MahaffeyStanford University School of Medicine, Stanford, CA, USA.
Paul ChangJanssen Scientific Affairs, Raritan, NJ, USA.
Gregg C FonarowUCLA Division of Cardiology, Los Angeles, CA, USA.
Michael J PencinaDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Jonathan P PicciniDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Eric D PetersonDuke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Clinical Research Institute · USHofstra University · USJanssen (United States) · USJefferson College · USMayo Clinic in Arizona · USStanford University · US

Funding

Using Data to Drive Change in National CV Care: The Duke CERTSU19HS021092 · AHRQ · DUKE UNIVERSITY · PI PETERSON, ERIC DAVID · 2011 to 2015
$4.2M
AHRQ HHS 1U19 HS021092
6 · The paper itself

Abstract

backgroundTherapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations.

objectivesWe sought to develop and validate a novel bleeding risk score using routinely available clinical information to predict major bleeding in a large, community-based AF population.

methodsWe analysed data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a prospective registry that enrolled incident and prevalent AF patients at 176 US sites. Using Cox proportional hazards regression, we identified factors independently associated with major bleeding among patients taking oral anticoagulation (OAC) over a median follow-up of 2 years (interquartile range = 1.6-2.5). We also created a numerical bedside risk score that included the five most predictive risk factors weighted according to their strength of association with major bleeding. The predictive performance of the full model, the simple five-item score, and two existing risk scores (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly, HAS-BLED, and anticoagulation and risk factors in atrial fibrillation, ATRIA) were then assessed in both the ORBIT-AF cohort and a separate clinical trial population, Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF).

resultsAmong 7411 ORBIT-AF patients taking OAC, the rate of major bleeding was 4.0/100 person-years. The full continuous model (12 variables) and five-factor ORBIT risk score (older age [75+ years], reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) both had good ability to identify those who bled vs. not (C-index 0.69 and 0.67, respectively). These scores both had similar discrimination, but markedly better calibration when compared with the HAS-BLED and ATRIA scores in an external validation population from the ROCKET-AF trial.

conclusionsThe five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.

Indexed as

Point-of-Care SystemsAgedAged, 80 and overAnticoagulantsAtrial FibrillationFemaleHemorrhageHumansMaleMiddle AgedProspective StudiesRegistriesRisk AssessmentRisk FactorsStrokeAnticoagulantsAnticoagulantsAtrial fibrillationMajor bleedingRisk prediction

Identifiers

PMID26424865
PMCPMC4670965
OpenAlexW2195719407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.